Novartis Pluvicto: $2.6B Run Rate, Q3 mHSPC Catalyst

Novartis (NVS) closed Friday at $155.01, down 0.7% on the week. The stock sits 38% above its 52-week low of $112.34 and 9% below its 52-week high of $170.46. With a $294.6 billion market cap, Novartis is one of the largest pharma companies on earth. The question for investors is whether the company’s radiopharmaceutical franchise can grow fast enough to justify paying near the top of the range.

I think the answer is yes, but not by much. Pluvicto is growing 43% year-over-year and has a Q3 2026 FDA decision pending that could quadruple its addressable patient population. The 177Lu-NeoB discontinuation that made headlines this week is a non-event for the stock. The real story is whether the mHSPC approval comes through and whether 225Ac-PSMA-617 succeeds in late-stage trials.

Pluvicto’s Q2: $651 Million and Climbing

Novartis reported Q2 2026 Pluvicto revenue of $651 million, up 43% year-over-year. That puts the drug at a $2.6 billion annual run rate. Lutathera, the company’s other approved radioligand therapy for neuroendocrine tumors, added $225 million in Q2, up 8%. Combined, the radiopharma franchise generated $876 million in the quarter, or about $3.5 billion annualized.

To put that in context: the global radiopharmaceutical market was valued at $14.2 billion in 2026 and is projected to reach $31 billion by 2032, according to Roots Analysis. Novartis’s $3.5 billion run rate gives it roughly 25% market share. No competitor comes close.

The 177Lu-NeoB Scrapping: Discipline, Not Disaster

Novartis quietly removed 177Lu-NeoB from its pipeline in its Q2 2026 investor presentation, posted July 22. The asset was a GRPR-targeted radioligand therapy in Phase 1/2 for breast cancer (NCT06247995) and Phase 2 for solid tumors. A company spokesperson confirmed the discontinuation to BioSpace, stating that “early clinical data did not support advancing it to the next stage of development.”

The key detail: the decision was not due to safety concerns. Novartis killed the program because the efficacy data was weak. That is target selection failure, not platform failure. GRPR (gastrin-releasing peptide receptor) is a different target from PSMA (prostate-specific membrane antigen), and the biology of breast cancer radioligand therapy is fundamentally different from prostate cancer. The discontinuation tells you nothing about Pluvicto’s prospects.

What it does tell you is that Novartis is disciplined about capital allocation. Rather than pouring hundreds of millions into a weak Phase 2 program, they cut it. The company still has 225Ac-PSMA-617 in late-stage development for post-lutetium mCRPC, plus several early-stage radioligand candidates for other solid tumors.

The Q3 2026 Catalyst: mHSPC Expansion

The FDA is expected to decide on Pluvicto’s expansion into metastatic hormone-sensitive prostate cancer (mHSPC) in Q3 2026. This is the near-term catalyst that matters most for Novartis, because it would expand the addressable population fourfold.

The PSMAddition Phase 3 trial enrolled 1,144 patients with PSMA-positive mHSPC across 20 countries. Pluvicto plus standard of care (ARPI + ADT) reduced the risk of radiographic progression or death by 28% versus standard of care alone: rPFS hazard ratio 0.72 (95% CI: 0.58, 0.90). The drug also delayed time to progression to mCRPC, with a hazard ratio of 0.70 (95% CI: 0.58, 0.84). Overall survival showed a positive trend: HR 0.84 (95% CI: 0.63, 1.13), though not yet statistically significant.

Grade 3 or higher adverse events were 50.7% in the Pluvicto arm versus 43% for standard of care. That is a meaningful toxicity increment, but consistent with the established safety profile.

Why does mHSPC matter? Approximately 172,000 men are diagnosed with mHSPC each year across the US, China, Japan, and major European markets. The current Pluvicto label covers only metastatic castration-resistant prostate cancer (mCRPC), a later stage of the disease. The mHSPC population is roughly four times larger than the mCRPC population, and patients are treated earlier in their disease course. An approval here would transform Pluvicto from a $2.6 billion drug into a potential $5 to $6 billion drug by 2028.

Competitive Picture: Novartis Owns the Category

The radiopharma sector is attracting heavy investment, but Novartis is the only large-cap pharma with meaningful commercial revenue. Bayer has Xofigo (radium-223) for mCRPC, but sales are declining and the pipeline is thin. AstraZeneca entered the space in March 2024 by acquiring Fusion Pharmaceuticals for up to $2.4 billion; it has no approved radiopharma products. Eli Lilly acquired Point Biopharma; same story. Bristol Myers Squibb is also building a radiopharma pipeline but has no approved products.

Here is the comp that matters: AstraZeneca paid $2.4 billion for Fusion, a pre-revenue company with early-stage clinical assets. Novartis generates $3.5 billion in annual radiopharma revenue from two approved drugs. The market is valuing AstraZeneca’s radiopharma optionality at $2.4 billion. Novartis’s existing radiopharma business is worth 1.5x AstraZeneca’s entire acquisition price, and Novartis gets 43% YoY growth on top.

For investors interested in the broader prostate cancer treatment space, our coverage of Pfizer’s Talzenna plus Xtandi priority review provides additional context on the competitive dynamics in prostate cancer drug development.

Valuation: Fairly Priced with Optionality

At $294.6 billion market cap and approximately $55 billion in annual revenue, Novartis trades at roughly 5.4x price-to-sales. AstraZeneca, the closest comp by market cap at approximately $289 billion, trades at a similar multiple. But Novartis has a structural advantage: its radiopharma franchise is growing at 43% while AstraZeneca’s oncology portfolio grows at roughly 15%.

The problem is that radiopharma is still only about 6% of Novartis’s total revenue. Even if Pluvicto doubles to $5 billion with mHSPC approval, that adds roughly $2.4 billion in revenue. At a 5x P/S multiple, that is $12 billion in incremental value, or about 4% upside on a $294.6 billion base. Meaningful but not transformative.

The bigger optionality is 225Ac-PSMA-617, Novartis’s next-generation actinium-based radioligand therapy for patients who have exhausted lutetium-based treatment. Actinium-225 emits alpha particles instead of beta particles, delivering higher energy over a shorter range. The physics matter: alpha particles deposit their energy within 2 to 10 cell diameters, compared to beta particles which travel 50 to 100 cell diameters. That means actinium can kill tumor cells with more precision while sparing surrounding healthy tissue. Novartis is currently enrolling two Phase 3 trials for 225Ac-PSMA-617 in post-lutetium mCRPC, with data expected in 2027 to 2028. If successful, this drug could extend Pluvicto’s franchise into the post-lutetium setting, adding another $1 to $2 billion in peak sales potential and creating a true franchise arc spanning a decade.

The broader radiopharma pipeline also includes early-stage assets targeting SSTR (somatostatin receptor) for neuroendocrine tumors and additional solid tumor targets beyond PSMA. Novartis has built a platform, not a single drug. The 177Lu-NeoB failure is a reminder that not every target works, but the platform approach means the company has multiple shots on goal.

Risks

The mHSPC PDUFA is the obvious near-term risk. The PSMAddition trial met its primary endpoint (rPFS), but the OS trend (HR 0.84) has not reached statistical significance. The FDA could request additional OS data before approval, delaying the launch by 12 to 18 months. That would not kill the expansion, but it would push the revenue ramp into 2028.

The toxicity increment is a secondary concern. A 7.7 percentage-point increase in Grade 3+ adverse events is not trivial. In the mHSPC setting, where patients are earlier in their disease course and have more treatment options, physicians may be selective about who gets Pluvicto versus simpler androgen deprivation therapy. That could limit the real-world penetration rate.

Verdict

Novartis at $155 is a Hold. The Pluvicto growth story is the best in radiopharma, and the Q3 mHSPC decision is a genuine catalyst. But at $294.6 billion market cap, the stock is already pricing in most of the good news. The 177Lu-NeoB discontinuation is a non-event. I would be a buyer on any pullback below $145, where the dividend yield (approximately 3.5%) plus the Pluvicto optionality creates a margin of safety. Above $160, the risk-reward is unfavorable ahead of a binary FDA decision.

For investors new to biotech catalysts, our guide to PDUFA dates explains how FDA decision deadlines drive stock price movements, and our biotech investing primer covers the fundamentals.